Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Artificial Intelligence Economy Intellectual Property

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears

Topics Economy

January 07, 2026

The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that...

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

Topics Artificial Intelligence Economy Stocks

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Topics Economy

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗

Topics Artificial Intelligence Economy Stocks

January 05, 2026

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Via Stocktwits

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

It's not time to give up on these companies yet.

Topics Economy Intellectual Property

2 Beaten-Down Stocks That Could Bounce Back in 2026 ↗

December 31, 2025

It's time for a celebration of the episodes that educated, amused, and enriched in 2025.

The Motley Fool Rule Breakers Besties of 2025 ↗

December 29, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics Economy Intellectual Property World Trade

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Topics Economy Government Intellectual Property

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Topics Economy

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On...

The Great Rotation: Small-Caps Break All-Time Highs as Investors Pivot from Mega-Tech

December 19, 2025

As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years,...

Topics Artificial Intelligence Economy Initial Public Offering

The Great Rotation: Why the Russell 2000 is Finally Outpacing the Giants in Late 2025

December 18, 2025

Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗

Topics Artificial Intelligence Bonds Economy

December 18, 2025

Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.

Via Stocktwits

2 Growth Stocks to Invest $1,000 in Right Now ↗

December 18, 2025

These stocks have promising assets in their portfolios that could help make their valuations soar in the future.

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.

1 Bold Prediction for Viking Therapeutics in 2026 ↗

December 16, 2025

The next 12 months will tell us more about their prospects.

2 Monster Stocks in the Making to Buy and Hold ↗

December 16, 2025

These players are well-positioned to potentially gain next year -- and over time.

My Top 10 Stocks to Buy for 2026 ↗

December 13, 2025

These stocks are underperforming the market this year, but that trend may not last for long.

Topics Artificial Intelligence

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 ↗

December 11, 2025

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and...

Topics Artificial Intelligence ETFs

What's Up With The Jump In Viking Therapeutics Stock? ↗

December 04, 2025

Via Benzinga

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon ↗

November 22, 2025

For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Topics Intellectual Property

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗

November 21, 2025

These stocks both have advanced in the double-digits in recent months.

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

These two healthcare stocks scan as bargains right now.

Topics Regulatory Compliance

2 No-Brainer Healthcare Stocks to Buy Now ↗

November 18, 2025